Login / Signup

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.

Sehhoon ParkJoon Ho ShimPeter G S MortimerSimon A SmithRobert E GodinSimon J HollingsworthHee-Jung KimHyun Ae JungJong-Mu SunWoong-Yang ParkJin Seok AhnMyung-Ju AhnSe-Hoon LeeKeunchil Park
Published in: Cancer (2020)
To the best of the authors' knowledge, the current study is the first biomarker-driven umbrella study conducted in patients with recurrent SCLC. Although the current study demonstrated the limited clinical efficacy of monotherapy, novel biomarker approaches using other cell cycle inhibitor(s) or combinations warrant further investigation.
Keyphrases
  • small cell lung cancer
  • cell cycle
  • clinical trial
  • systematic review
  • squamous cell carcinoma
  • randomized controlled trial
  • study protocol
  • open label
  • combination therapy
  • phase iii